Eur Heart J 2020;41:255-323
February 5, 2024
Expected outcomes based on trial data: Average weight loss of 24.2% at 48 weeks (phase 2) Average weight loss of 28.7% at 68 weeks (phase 3, TRIUMPH-4) 100% of participants achieved 5% or greater weight loss 93% achieved 10% or greater 83% achieved 15% or greater Moderate weight loss protocol (8mg target) For researchers who want significant weight loss but have a lower tolerance for side effects, stopping the escalation at 8mg is a validated approach
Weight loss results vary depending on factors such as: For many users, progress tends to happen steadily over time rather than rapidly
These effects enhanced the cytotoxicity of CD8+ T cells and their capacity to eliminate tumor cells, thereby augmenting the antitumor efficacy of PD-1 inhibitors (109,110)
Dietary Adjustments: Eating smaller, more frequent meals and avoiding high-fat or spicy foods can help reduce gastrointestinal discomfort and insulin resistance. Hydration: Staying hydrated during your treatment is essential, especially if you experience gastrointestinal adverse events like vomiting or diarrhea. Daily Exercise: Consistent activity like walking, jogging, or resistance training can strengthen bones and counteract both fat accumulation and bone density loss
